These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

336 related items for PubMed ID: 15328168

  • 1. Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results.
    Leonard JP, Coleman M, Ketas JC, Chadburn A, Furman R, Schuster MW, Feldman EJ, Ashe M, Schuster SJ, Wegener WA, Hansen HJ, Ziccardi H, Eschenberg M, Gayko U, Fields SZ, Cesano A, Goldenberg DM.
    Clin Cancer Res; 2004 Aug 15; 10(16):5327-34. PubMed ID: 15328168
    [Abstract] [Full Text] [Related]

  • 2. Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma.
    Leonard JP, Coleman M, Ketas JC, Chadburn A, Ely S, Furman RR, Wegener WA, Hansen HJ, Ziccardi H, Eschenberg M, Gayko U, Cesano A, Goldenberg DM.
    J Clin Oncol; 2003 Aug 15; 21(16):3051-9. PubMed ID: 12837807
    [Abstract] [Full Text] [Related]

  • 3. Dose-fractionated radioimmunotherapy in non-Hodgkin's lymphoma using DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab.
    Lindén O, Hindorf C, Cavallin-Ståhl E, Wegener WA, Goldenberg DM, Horne H, Ohlsson T, Stenberg L, Strand SE, Tennvall J.
    Clin Cancer Res; 2005 Jul 15; 11(14):5215-22. PubMed ID: 16033839
    [Abstract] [Full Text] [Related]

  • 4. Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma.
    Strauss SJ, Morschhauser F, Rech J, Repp R, Solal-Celigny P, Zinzani PL, Engert A, Coiffier B, Hoelzer DF, Wegener WA, Teoh NK, Goldenberg DM, Lister TA.
    J Clin Oncol; 2006 Aug 20; 24(24):3880-6. PubMed ID: 16864854
    [Abstract] [Full Text] [Related]

  • 5. Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma.
    Leonard JP, Coleman M, Ketas J, Ashe M, Fiore JM, Furman RR, Niesvizky R, Shore T, Chadburn A, Horne H, Kovacs J, Ding CL, Wegener WA, Horak ID, Goldenberg DM.
    J Clin Oncol; 2005 Aug 01; 23(22):5044-51. PubMed ID: 15955901
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Low- versus high-dose radioimmunotherapy with humanized anti-CD22 or chimeric anti-CD20 antibodies in a broad spectrum of B cell-associated malignancies.
    Behr TM, Wörmann B, Gramatzki M, Riggert J, Gratz S, Béhé M, Griesinger F, Sharkey RM, Kolb HJ, Hiddemann W, Goldenberg DM, Becker W.
    Clin Cancer Res; 1999 Oct 01; 5(10 Suppl):3304s-3314s. PubMed ID: 10541379
    [Abstract] [Full Text] [Related]

  • 8. Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study.
    Advani A, Coiffier B, Czuczman MS, Dreyling M, Foran J, Gine E, Gisselbrecht C, Ketterer N, Nasta S, Rohatiner A, Schmidt-Wolf IG, Schuler M, Sierra J, Smith MR, Verhoef G, Winter JN, Boni J, Vandendries E, Shapiro M, Fayad L.
    J Clin Oncol; 2010 Apr 20; 28(12):2085-93. PubMed ID: 20308665
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Pharmacokinetics, dosimetry, and initial therapeutic results with 131I- and (111)In-/90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphoma.
    Juweid ME, Stadtmauer E, Hajjar G, Sharkey RM, Suleiman S, Luger S, Swayne LC, Alavi A, Goldenberg DM.
    Clin Cancer Res; 1999 Oct 20; 5(10 Suppl):3292s-3303s. PubMed ID: 10541378
    [Abstract] [Full Text] [Related]

  • 11. Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties.
    Carnahan J, Wang P, Kendall R, Chen C, Hu S, Boone T, Juan T, Talvenheimo J, Montestruque S, Sun J, Elliott G, Thomas J, Ferbas J, Kern B, Briddell R, Leonard JP, Cesano A.
    Clin Cancer Res; 2003 Sep 01; 9(10 Pt 2):3982S-90S. PubMed ID: 14506197
    [Abstract] [Full Text] [Related]

  • 12. High-Dose celecoxib and metronomic "low-dose" cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphoma.
    Buckstein R, Kerbel RS, Shaked Y, Nayar R, Foden C, Turner R, Lee CR, Taylor D, Zhang L, Man S, Baruchel S, Stempak D, Bertolini F, Crump M.
    Clin Cancer Res; 2006 Sep 01; 12(17):5190-8. PubMed ID: 16951238
    [Abstract] [Full Text] [Related]

  • 13. High rates of durable responses with anti-CD22 fractionated radioimmunotherapy: results of a multicenter, phase I/II study in non-Hodgkin's lymphoma.
    Morschhauser F, Kraeber-Bodéré F, Wegener WA, Harousseau JL, Petillon MO, Huglo D, Trümper LH, Meller J, Pfreundschuh M, Kirsch CM, Naumann R, Kropp J, Horne H, Teoh N, Le Gouill S, Bodet-Milin C, Chatal JF, Goldenberg DM.
    J Clin Oncol; 2010 Aug 10; 28(23):3709-16. PubMed ID: 20625137
    [Abstract] [Full Text] [Related]

  • 14. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
    Huang HQ, Bu Q, Xia ZJ, Lin XB, Wang FH, Li YH, Peng YL, Pan ZH, Wang SS, Lin TY, Jiang WQ, Guan ZZ.
    Ai Zheng; 2006 Apr 10; 25(4):486-9. PubMed ID: 16613686
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Epratuzumab: targeting B-cell malignancies through CD22.
    Coleman M, Goldenberg DM, Siegel AB, Ketas JC, Ashe M, Fiore JM, Leonard JP.
    Clin Cancer Res; 2003 Sep 01; 9(10 Pt 2):3991S-4S. PubMed ID: 14506198
    [Abstract] [Full Text] [Related]

  • 17. Preclinical and clinical evaluation of epratuzumab (anti-CD22 IgG) in B-cell malignancies.
    Leonard JP, Goldenberg DM.
    Oncogene; 2007 May 28; 26(25):3704-13. PubMed ID: 17530024
    [Abstract] [Full Text] [Related]

  • 18. A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma.
    Khan KD, Emmanouilides C, Benson DM, Hurst D, Garcia P, Michelson G, Milan S, Ferketich AK, Piro L, Leonard JP, Porcu P, Eisenbeis CF, Banks AL, Chen L, Byrd JC, Caligiuri MA.
    Clin Cancer Res; 2006 Dec 01; 12(23):7046-53. PubMed ID: 17145827
    [Abstract] [Full Text] [Related]

  • 19. Durable complete responses from therapy with combined epratuzumab and rituximab: final results from an international multicenter, phase 2 study in recurrent, indolent, non-Hodgkin lymphoma.
    Leonard JP, Schuster SJ, Emmanouilides C, Couture F, Teoh N, Wegener WA, Coleman M, Goldenberg DM.
    Cancer; 2008 Nov 15; 113(10):2714-23. PubMed ID: 18853418
    [Abstract] [Full Text] [Related]

  • 20. Monoclonal antibodies for the treatment of hematologic malignancies: clinical trials in Japan.
    Tobinai K.
    Cancer Chemother Pharmacol; 2003 Jul 15; 52 Suppl 1():S90-6. PubMed ID: 12819934
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.